GLS-5700 in Dengue Virus Seropositive Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

June 30, 2018

Conditions
HealthyZika
Interventions
BIOLOGICAL

GLS-5700

GLS 5700 at 2 mg DNA/dose

BIOLOGICAL

Placebo

Trial Locations (3)

00874

Clinical Research of Puerto Rico, San Juan

00909

Fundacion De Investigation, San Juan

00936

University of Puerto Rico, San Juan

Sponsors
All Listed Sponsors
collaborator

Inovio Pharmaceuticals

INDUSTRY

lead

GeneOne Life Science, Inc.

INDUSTRY

NCT02887482 - GLS-5700 in Dengue Virus Seropositive Adults | Biotech Hunter | Biotech Hunter